US · IFRX · BIOTECHNOLOGY
InflaRx N.V. (IFRX) intrinsic value and stock valuation
$1.04as of 2026-11-21 · Mkt cap 132.91M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
InflaRx N.V. DCF and intrinsic value
InvestorsCraft values IFRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IFRX’s statements →
InflaRx N.V. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $30K | $170K | $60K | $0.00 | $0.00 |
| Operating income | -$-48.26M | -$-52.91M | -$-44.59M | -$-32.24M | -$-47.63M |
| Net income | -$-45.63M | -$-46.06M | -$-42.67M | -$-29.48M | -$-45.63M |
| EPSd | -$-678.11K | -$-781.74K | -$-776.67K | -$-666.82K | -$-1.1M |
| Operating cash flow | -$-33.92M | -$-48.56M | -$-37.81M | -$-33.74M | -$-39.94M |
| Capital expenditure | -$-110K | -$-50K | -$-80K | -$-160K | -$-40K |
| Free cash flow | -$-34.03M | -$-48.6M | -$-37.89M | -$-33.91M | -$-39.97M |
| Total assets | $55.2M | $76M | $120.2M | $102.4M | $125.1M |
| Total debt | $900K | $810K | $1.12M | $1.36M | $1.43M |
| Net debt | -$-15.12M | -$-17.57M | -$-11.65M | -$-14.91M | -$-24.82M |
| Total equity | $41.5M | $61.4M | $102.6M | $88.4M | $105.3M |
| Cash and short-term investments | $46.4M | $18.4M | $12.8M | $81.8M | $83.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $30K | $170K | $60K | $0.00 | $0.00 |
| Cost of revenue | $7.27M | $3.32M | $530K | $0.00 | $0.00 |
| Gross profit | -$-7.24M | -$-3.15M | -$-470K | $0.00 | $0.00 |
| Research and development expenses | $25.7M | $35.4M | $41M | $37.5M | $35.7M |
| Selling, general and administrative expenses | $17.6M | $19.3M | $16.1M | $14.3M | $11.4M |
| Other expenses | -$-2.27M | -$-4.94M | -$-13.02M | -$-19.63M | $500K |
| Operating expenses | $41M | $49.8M | $44.1M | $32.2M | $47.6M |
| Cost and expenses | $48.3M | $53.1M | $44.7M | $32.2M | $47.6M |
| Interest income | $1.77M | $3.2M | $3.8M | $610K | $110K |
| Interest expense | $40K | $20K | $40K | $50K | $20K |
| Depreciation and amortization | $420K | $490K | $570K | $600K | $670K |
| Ebitda | -$-45.16M | -$-45.55M | -$-42.06M | -$-28.84M | -$-44.94M |
| Operating income | -$-48.26M | -$-52.91M | -$-44.59M | -$-32.24M | -$-47.63M |
| Total other income/expenses, net | $2.64M | $6.85M | $1.93M | $2.75M | $2M |
| Income before tax | -$-45.62M | -$-46.06M | -$-42.67M | -$-29.48M | -$-45.63M |
| Income tax expense | $10K | $10K | $0.00 | $0.00 | $0.00 |
| Net income | -$-45.63M | -$-46.06M | -$-42.67M | -$-29.48M | -$-45.63M |
| Weighted average shares outstanding | $67.3M | $58.9M | $54.9M | $44.2M | $41.6M |
| Weighted average diluted shares outstanding | $67.3M | $58.9M | $54.9M | $44.2M | $41.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $46.4M | $18.4M | $12.8M | $81.8M | $83.4M |
| Net receivables | $1.43M | $0.00 | $0.00 | $1.43M | $1.28M |
| Inventory | $0.00 | $6.9M | $11.4M | $0.00 | $0.00 |
| Total current assets | $53.6M | $71.7M | $109.5M | $97.4M | $95.7M |
| Property, plant and equipment, net | $1.15M | $1.01M | $1.36M | $1.64M | $1.68M |
| Goodwill and intangible assets | $40K | $10K | $40K | $140K | $240K |
| Long-term investments | $240K | $3.09M | $9.05M | $2.9M | $27.2M |
| Total non-current assets | $1.58M | $4.36M | $10.7M | $4.99M | $29.5M |
| Total assets | $55.2M | $76M | $120.2M | $102.4M | $125.1M |
| Accounts payable | $5.4M | $3.41M | $5.1M | $4.99M | $1.69M |
| Short-term debt | $260K | $410K | $370K | $370K | $370K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $6.21M | $8.3M |
| Total current liabilities | $13M | $14.2M | $16.8M | $13M | $18.8M |
| Long-term debt | $640K | $400K | $750K | $990K | $1.07M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $680K | $440K | $780K | $1.02M | $1.1M |
| Capital lease obligations | $640K | $810K | $1.12M | $1.36M | $1.43M |
| Total liabilities | $13.7M | $14.6M | $17.6M | $14.1M | $19.9M |
| Common stock | $8.67M | $7.12M | $7.07M | $5.36M | $5.3M |
| Retained earnings | -$-377.67M | -$-332.19M | -$-286.13M | -$-243.46M | -$-213.98M |
| Accumulated other comprehensive income (loss) | $48.5M | $51.6M | $47.4M | $36.6M | $30.6M |
| Total equity | $41.5M | $61.4M | $102.6M | $88.4M | $105.3M |
| Total investments | $30.7M | $3.09M | $9.05M | $68.4M | $84.4M |
| Total debt | $900K | $810K | $1.12M | $1.36M | $1.43M |
| Net debt | -$-15.12M | -$-17.57M | -$-11.65M | -$-14.91M | -$-24.82M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-43.83M | -$-46.06M | -$-42.67M | -$-29.48M | -$-45.63M |
| Depreciation and amortization | $400K | $490K | $570K | $600K | $670K |
| Stock-based compensation | $0.00 | $4.07M | $3.41M | $6.04M | $4.33M |
| Change in working capital | $4.66M | -$-2.28M | $1M | -$-9.77M | $1.54M |
| Accounts receivable | $2.12M | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $6.63M | $4.47M | -$-11.37M | $0.00 | $0.00 |
| Accounts payable | -$-5.76M | $0.00 | $0.00 | -$-3.52M | $320K |
| Net cash provided by operating activities | -$-33.92M | -$-48.56M | -$-37.81M | -$-33.74M | -$-39.94M |
| Investments in property, plant and equipment | -$-110K | -$-50K | -$-80K | -$-160K | -$-40K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-19.52M | $40K |
| Net cash used for investing activities | $3.11M | $52.4M | -$-17.7M | $19.4M | -$-25.95M |
| Common stock issued | $32.4M | $1.1M | $56.5M | $2.35M | $65.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $32M | $390K | $53M | $1.94M | $61.6M |
| Net change in cash | -$-180K | $5.61M | -$-3.5M | -$-9.98M | $280K |
| Cash at end of period | $16M | $18.4M | $12.8M | $16.3M | $26.3M |
| Operating cash flow | -$-33.92M | -$-48.56M | -$-37.81M | -$-33.74M | -$-39.94M |
| Capital expenditure | -$-110K | -$-50K | -$-80K | -$-160K | -$-40K |
| Free cash flow | -$-34.03M | -$-48.6M | -$-37.89M | -$-33.91M | -$-39.97M |
Line items
Line items
Line items
About InflaRx N.V.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
- CEO
- Niels C. Riedemann
- Employees
- 65
- Beta
- 2.45
Explore
Frequently asked questions
What is the intrinsic value of InflaRx N.V. (IFRX)?
InvestorsCraft does not currently publish an intrinsic value for IFRX. How the IC value is calculated.
Is IFRX undervalued?
InvestorsCraft does not publish an undervaluation signal for IFRX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.